Expert Opinion on Biological Therapy

Medicinally useful proteins – enhancing the probability of technical success in the clinic
pp. 149-151(3)
Author: Armen B Shanafelt

Ethical and regulatory aspects of embryonic stem cell research
pp. 153-162(10)
Author: KK Jain

Natural killer: can they be useful as adoptive immunotherapy for cancer?
pp. 163-172(10)
Authors: Sally Arai; Hans-G Klingemann

RNA transfer and its use in dendritic cell-based immunotherapy
pp. 173-181(9)
Authors: Tatjana C Gust; Martin Zenke

Gene therapy for the treatment of mitochondrial DNA disorders
pp. 183-194(12)
Author: Robert W Taylor

Development of mammalian artificial chromosomes for the treatment of genetic diseases: Sandhoff and Krabbe diseases
pp. 195-206(12)
Authors: Bruce A Bunnell; Reza Izadpanah; Harry C Ledebur Jr; Carl F Perez

Antisense approaches for inhibiting respiratory syncytial virus
pp. 207-220(14)
Author: Hagen Cramer

siRNA as a route to new cancer therapies
pp. 221-224(4)
Authors: Maya Ameyar-Zazoua; Valentina Guasconi; Slimane Ait-Si-Ali

Recent developments in the production of human therapeutic proteins in eukaryotic algae
pp. 225-235(11)
Authors: Scott E Franklin; Stephen P Mayfield

TransMabs: cell-penetrating antibodies, the next generation
pp. 237-241(5)
Authors: Sybille Muller; Yunfeng Zhao; Thomas L Brown; Alton C Morgan; Heinz Kohler

Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis
pp. 243-251(9)
Authors: Leendert A Trouw; Mohamed R Daha

From mice to humans – murine intelligence for human CD8⁺ T cell vaccine design
pp. 263-271(9)
Authors: David C Tscharke; Andreas Suhrbier

Recent developments in Neisseria meningitidis group A conjugate vaccines
pp. 273-280(8)
Author: Carl E Frasch